A Phase 1 interventional study of INV-347 in Obesity, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Obesity by Novo Nordisk A/S — 51 open to participants now, 69 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.
Among the 210 studies in Obesity by Novo Nordisk A/S, this one is the 113th largest by planned enrollment of the 169 interventional ones that give a count, is one of 22 that started in 2025, is one of 87 in phase 1, reaches primary completion later than 25 of the 68 other live ones, and was the 148th registered.
11,560 studies on the registry are indexed under Obesity; 2,059 are open to participants now.
Browse Obesity studies →51 of the 210 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Austria
Ages 18–64
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 1,350 Obesity studies recruiting now, 382 (28%) set no upper age limit and 864 (64%) stop at 75 or younger; 168 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 15 · Phase 3 62 · Phase 4 4
First in 2007; this study’s year is marked. 22 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 91 is above the median of 68 across 9,040 interventional studies indexed under Obesity.
Median enrollment 134 across the 169 interventional studies, 1,260 across the 41 observational. Of the 138 that completed or were terminated, 39 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
26 of the studies in Obesity by Novo Nordisk A/S that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
Add all 26 to your calendar (.ics) → With an account.
Among the 210 studies in Obesity by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study has no exclusion criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.
Drug: INV-347
Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.
Number of adverse events
Number of events
Time frame: From the end-of-study participation in INV-CL-108 (week 0) to completion of the end-of-study visit (up to week 104 from enrolment)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Sep 2027, 25 months after the start.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 25 months is above that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.